AstraZeneca Launches Call for Innovation Partners in Latin America to Advance Healthcare Ecosystem Collaboration
AstraZeneca
Biopharmaceutical Manufacturer
AstraZeneca-supported
Healthcare Innovation Ecosystem iCampus,
Gathering forces from all sectors, including government, industry, academia, research, medicine, and investment，
Continuously recruiting innovative partners,
Promote resource sharing and collaborative development,
Cultivate new technologies, new business forms, and new models,
To help the high-quality development of China's health industry,
Promote the overseas expansion of Chinese innovative companies and their innovative achievements.
In July this year, a delegation of Chinese enterprises traveled to Brazil for a 5-day cross-border health innovation ecosystem exchange and cooperation event, helping16 institutionsChinese companies have gained a deep understanding of the operating policies, business environment, industry hotspots, and ecosystem in Brazil's local healthcare sector. During this period,China and Brazil have reached multiple collaborations in areas such as innovative introductions in the Brazilian market, product promotion, ecological co-construction, digital healthcare, and patient services.
AstraZeneca signed a strategic cooperation agreement with IPT, one of the largest public technology research institutions in Brazil, to jointly establish the Brazil Healthcare Innovation Center (IPE).
The International Life Science Innovation Park iCampus has simultaneously established a partnership with IPE, jointly committed to building a bilateral innovation ecosystem between Brazil and China.
The digital healthcare enterprise representative of the visiting delegation, Lida Rongyi, signed a Memorandum of Understanding with AstraZeneca Brazil. Both parties will collaborate on the digital transformation of Brazil's health system in the future.
The Chinese enterprises in the visiting delegation have all signed memorandums of cooperation with AstraZeneca Brazil, committing to introduce high-quality innovative achievements from China to the Brazilian market. This aims to further promote the enhancement of the local healthcare industry and economic development, jointly improve the efficiency and innovation capabilities of Brazil's health system, and facilitate the formation of a Sino-Brazilian healthcare industry ecosystem.
Next, in the first quarter of 2024, AstraZeneca Brazil will leadBrazil, Argentina, Mexico, and ColombiaRepresentatives from government, industry, academia, research, medicine, and investment have arrived in China for a return visit, and at that time willCentering on China's national health industry policies and global healthcare innovation and development trends, engage in forward-looking and authoritative exchange dialogues with leading enterprises in the industry and innovative ecosystem partners in the medical and health field.！
To Be Launched
"Recruitment for Innovative Enterprises Intending to Enter the Latin American Market"
NEWS
”
Directions for Innovation Project Recruitment
1.Recruitment Background:
AstraZeneca Brazil and its Latin American partners are focusing on innovation in the public health sector, hoping to find leading companies in the corresponding field in China as partners through this exchange. They are dedicated to helping patients solve clinical pain points in "screening, diagnosis, treatment, and management" through big data analysis and efficient, cost-effective solutions.
2. Recruitment Needs：Partners with intentions to expand into Latin America
Demand 1: Screening and diagnosis for chronic kidney disease, cancer (lung, breast), heart disease, and rare diseases
Diseases applicable to in-hospital scenariosTesting Equipment；
Diseases applicable to primary hospital settingsInspection and Testing Equipment / Early Screening and Diagnosis Solution Platform, to expand the accessibility of early diagnosis;
Innovative enterprises that can enhance the risk prediction and early screening capabilities for the aforementioned diseases through data algorithms;
Demand Two: Solutions for the respiratory field including COPD/asthma:
Product Direction: Digital diagnostics, POCT testing equipment, digital therapeutics or assistive treatment devices;
ProductMust have: Respiratory function analysis (FEV1, FVC) and the ability to determine abnormal indicators;
ProductBest to have: Differential diagnosis in the field of respiratory diseases (e.g., COPD, asthma) and capable of providing auxiliary diagnostic recommendations;
ProductTarget Audience: Patients with respiratory symptoms but not yet diagnosed;
Requirement Three: Public Health Medical Solutions
Based on data and cutting-edge diagnostic and treatment technologies, can provideEfficient Diagnosis and Treatment Solutions for Primary Healthcare Settings
TargetingTropical DiseasesHealthcare solutions for different stages of diagnosis and treatment
3.Expected Cooperation Standards:
Solution/Platform can collaborate on clinical trials in Brazil through local research and ANVISA approval.
Be able to set up an office in Brazil
*ANVISA is the Brazilian National Health Surveillance Agency, regulating medical devices.
4. Recruitment Needs Deadline:
December 2023
Other Innovative Project Collaboration Needs
3. "Partner Recruitment | AstraZeneca Releases Innovation Needs in the Field of Metabolic Diseases"
Project Submission Method
The1Step
Scan the code to fill out the questionnaire and apply for needs.
The2Step
SendBP to: iCampus@astrazeneca.com
The3Step
The project team will conduct an initial screening and reply by email within 5 working days to further understand the relevant information.
The4Step
After being reviewed by the project team,Will send targeted invitations to matching companies
For information inquiries, please contact Yolanda Han:
iCampus@astrazeneca.com
13681771603
Project Cooperation Direction
Outstanding projects will have the opportunity to join.AstraZeneca Latin America Ecosystem, and obtain the following cooperation opportunities:
AstraZeneca Latin America Commercial Collaboration
AstraZeneca Brazil can provide local commercial cooperation partnerships, through which AstraZeneca Brazil will extend solutions to the existing Latin American ecosystem and offer financial support for some pilot/POC projects.
Overseas Business Expansion Support (Brazil)
AstraZeneca Brazil can provide a local team (headquarters and sales force) to assist partners in expanding their market and business in Brazil.
Empowering Overseas Event Industry Exchange
Participating in this Latin America group visit to China exchange program allows for in-depth communication with representatives from the political, industrial, academic, research, medical, and investment sectors of the Latin American ecosystem, exploring future collaboration opportunities.
Outstanding projects will have the opportunity to join.AstraZeneca Ecosystem iCampus, and obtain the following cooperation opportunities:
AstraZeneca Commercial Cooperation
Integrate integrated diagnostic and treatment solutions such as AstraZeneca's National Standardized Metabolic Disease Management Center (MMC), the full-course management of chronic kidney disease in the nephrology product line, and the Community Chronic Disease Patient Management Center (iCDMC) to expand commercial channels.
Expert Collaboration
Link with the team of top experts in disease treatment fields across China, led by academicians and specialists, for technical/industry/cooperation discussions.
Fund Investment
Engage with iCampus incubation fund for evaluation and对接, focusing on financing projects that feature technological innovations synergistic with AstraZeneca's therapeutic areas.
Industry/Academic Activity Synergy
Invited to participate in AstraZeneca's various ecosystem summits, industry discussions, academic roadshows, and partnership matchmaking related to the theme.
Park Entry
Opportunities to access the International Life Science Innovation Parks in 8 cities across China (Wuxi, Beijing, Shanghai, Guangzhou, Hangzhou, Chengdu, Yixing, Qingdao), gaining services such as space, policy support, acceleration programs, and financing.
Going Overseas
Relying on AstraZeneca's global commercial network, expand overseas markets, particularly in Belt and Road and Latin American countries.
About Us
This year marks the 30th anniversary of AstraZeneca's entry into China. Over the years, AstraZeneca has achieved mutual growth with the industry through clear strategic planning and innovation-driven development. By creating three innovative "horses" — the China Smart Health Innovation Center (CCiC), the International Life Science Innovation Park (iCampus), and the AstraZeneca Zhongjin Healthcare Industry Fund — AstraZeneca has built an open, cooperative, win-win, and global health innovation ecosystem. These efforts aim to promote local innovations that benefit patients in China and globally, while also fostering substantial development in regional economies and the broader healthcare industry.
Create an Innovative Model
· Implemented in thousands of hospitals across China
· Benefit tens of millions of patients
· Some solutions go global
Incubate Innovation Ecosystem
· 140+入驻企业
· Nearly 20 Global Collaborative Innovation Networks
· Regional Ecosystem Summit
Create an Innovative Model
· Over 3 billion RMB under management
· Raise $1 billion
· Invested in nearly 20 innovative enterprises
Scan the code to learn more about the residency information.
Become a part of the world's leading life science innovation ecosystem
— About the International Life Science Innovation Park —
International Life Science Innovation Park will become a platform for innovative enterprises at home and abroad to achieve project implementation, innovation incubation, and business acceleration.And a one-stop innovative empowerment platform for scaling up. With the support of multiple parties including the government, industry, academia, research, medical, and investment sectors, it is committed to becoming the preferred park for domestic and international life science innovators to cultivate the Chinese market and connect with the global market, gathering global wisdom to contribute to Healthy China.
